Skip to main content
Disease burden, management strategies, and unmet needs in α-thalassemia due to hemoglobin H disease.
Improving healthspan among people with sickle cell disease: Leveraging precision health in an era of treatments with curative intent.
Mortality in adults with sickle cell disease: Results from the sickle cell disease implementation consortium (SCDIC) registry.
Long-term outcomes after unrelated donor transplantation for severe sickle cell disease on the BMT CTN 0601 trial.
Defining curative endpoints for transfusion-dependent β-thalassemia in the era of gene therapy and gene editing.
Defining curative endpoints for sickle cell disease in the era of gene therapy and gene editing.
The FLT3N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib.
Pregnancy-related thromboembolism in women with sickle cell disease: An analysis of National Medicaid Data.
Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study.
Clinical Features Associated with Thrombotic Events in Children with Myeloproliferative Neoplasms.